செர்ஜி இளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from செர்ஜி இளம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In செர்ஜி இளம் Today - Breaking & Trending Today
DNA Explainer: Jeff Bezos to Elon Musk - How billionaires are trying to achieve immortality dnaindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dnaindia.com Daily Mail and Mail on Sunday newspapers.
Luke Storey commits his first hack at dawn precisely when the sun crests the horizon at a 30-degree angle, providing a supercharged light that he swears optimally dials his circadian rhythm and neurotransmitters. Sungazing is often followed by a ten-minute plunge in an industrial freezer full of 40-degree water a jerry-rigged ice bath. After toweling off, the rangy, six-foot-three 50-year-old then ascends to the top of his Laurel Canyon property where he has converted a toolshed into a new-age gym that looks like it was outfitted by someone who has watched the Iron Man trilogy a few too many times. There’s a hyperbaric chamber that he meditates in before he flips on the mitochondria-boosting light panels that hang from the walls. Naked, he stands for five minutes on a full-body-vibration plate before he plops into a chair covered by an infrared heating pad and plugs himself into several gizmos as he absorbs the natural energies emitted from a $15,000 machine called the Bioc ....
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing News provided by Share this article Share this article PITTSBURGH, Dec. 30, 2020 /PRNewswire/ LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD). ....